Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Deferred Taxes (2024 - 2025)

Theravance Biopharma (TBPH) has disclosed Deferred Taxes for 2 consecutive years, with $994000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Deferred Taxes rose 1004.44% to $994000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$18.1 million, a N/A change, with the full-year FY2024 number at -$7.6 million, down 336.14% from a year prior.
  • Deferred Taxes was $994000.0 for Q3 2025 at Theravance Biopharma, up from -$10.7 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $994000.0 in Q3 2025 to a low of -$10.7 million in Q2 2025.